These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24189264)

  • 1. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
    Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
    Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
    Goldner T; Zimmermann H; Lischka P
    Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
    Wildum S; Zimmermann H; Lischka P
    Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
    Chou S; Satterwhite LE; Ercolani RJ
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
    Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
    J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
    Lischka P; Michel D; Zimmermann H
    J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
    Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
    Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
    Chou S
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
    Chou S
    Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical effects of letermovir (Prevymis
    Ogawa M; Eto T
    Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
    Lischka P; Zhang D; Holder D; Zimmermann H
    Antiviral Res; 2016 Aug; 132():204-9. PubMed ID: 27345658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
    Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
    J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
    Jo H; Kwon DE; Han SH; Min SY; Hong YM; Lim BJ; Lee KH; Jo JH
    J Infect Dis; 2020 Apr; 221(9):1480-1487. PubMed ID: 31802131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
    Piret J; Goyette N; Boivin G
    Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.
    Marschall M; Stamminger T; Urban A; Wildum S; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1135-7. PubMed ID: 22106211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
    Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
    Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.